Sentinel lymph node biopsy: is it possible to reduce false negative rates by excluding patients with nodular melanoma?
AffiliationDepartment of Academic Surgery, Cork University Hospital, Ireland., email@example.com
Aged, 80 and over
False Negative Reactions
Neoplasm Recurrence, Local/*pathology
*Sentinel Lymph Node Biopsy
MetadataShow full item record
CitationSurgeon. 2006 Jun;4(3):153-7.
JournalThe surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
AbstractOBJECTIVE: The aim of this study was to review the outcome of sentinel lymph node biopsy (SLNB) in patients with melanoma and to delineate whether patients with nodular melanoma are more likely to develop nodal recurrence despite negative SLNB. METHODS: Consecutive patients with cutaneous melanoma undergoing SLNB were identified from a departmental database between 1997 and 2005. Factors including demographic data, site, histological subtype, depth and outcome were examined. RESULTS: Of 131 patients, 103 were node negative and eligible for study. The median age was 53 (16-82) years with 46 patients being male (45%) and 57 female (55%). Primary melanoma sites included lower limb (49; 48%), upper limb (29; 28%), head (12; 11%), trunk (7; 7%) and back (6; 6%). The median Breslow thickness was 2mm. Superficial spreading accounted for 43% of melanoma with nodular accounting for 42%. Median follow-up was 40 (3-90) months. Of 20 relapses, seven recurred in the same nodal basin, three were satellite recurrences, one recurred with both satellite and nodal lesions simultaneously, and nine experienced haematogenous spread. Of the eight patients who developed recurrence in the same nodal basin, four were of nodular histological subtype (p=NS). All of the three patients with satellite lesions had nodular melanoma histologically (p=0.02). When nodal and satellite recurrences were combined, eight of 11 were histologically nodular (p=0.01). CONCLUSIONS: This study indicates that lymphatic recurrence occurs more often in SLNB negative patients with nodular melanoma. Further evaluation of the inclusion criteria for sentinel node biopsy is warranted.
- Cervical sentinel lymph node biopsy for melanomas of the head and neck and upper thorax.
- Authors: Wagner JD, Park HM, Coleman JJ 3rd, Love C, Hayes JT
- Issue date: 2000 Mar
- Nodular Histologic Subtype and Ulceration are Tumor Factors Associated with High Risk of Recurrence in Sentinel Node-Negative Melanoma Patients.
- Authors: Faut M, Wevers KP, van Ginkel RJ, Diercks GF, Hoekstra HJ, Kruijff S, Been LB, van Leeuwen BL
- Issue date: 2017 Jan
- Sentinel lymph node biopsy is indicated for patients with thick clinically lymph node-negative melanoma.
- Authors: Yamamoto M, Fisher KJ, Wong JY, Koscso JM, Konstantinovic MA, Govsyeyev N, Messina JL, Sarnaik AA, Cruse CW, Gonzalez RJ, Sondak VK, Zager JS
- Issue date: 2015 May 15
- Sentinel Lymph Node Biopsy for Cutaneous Head and Neck Melanoma: Mapping the Parotid Gland.
- Authors: Picon AI, Coit DG, Shaha AR, Brady MS, Boyle JO, Singh BB, Wong RJ, Busam KJ, Shah JP, Kraus DH
- Issue date: 2016 Dec
- Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma.
- Authors: Wagner JD, Ranieri J, Evdokimow DZ, Logan T, Chuang TY, Johnson CS, Jung SH, Wenck S, Coleman JJ 3rd
- Issue date: 2003 Aug